Core Viewpoint - Phibro Animal Health reported strong financial performance in the second quarter, with significant revenue and adjusted net income growth, leading to raised guidance for future financial metrics [2][5]. Financial Performance - The company achieved 21% revenue growth and 60% growth in adjusted net income, generating $94 million in revenue for the quarter [2][5]. - Following a robust first half, the company raised its guidance for revenue, EBITDA, and adjusted net income, reflecting positive investor feedback [1][5]. Business Segments - Continued growth was noted in vaccines (13% growth) and nutritional specialties (9% growth) for the quarter [1]. - The legacy Medicated Feed Additives (MFA) business experienced a 5% decline due to order timing but would have grown approximately 3% when normalized [1]. Strategic Focus - Management is prioritizing higher-margin growth in vaccines and nutritional specialties, aiming for mid-to-high single-digit growth and margin expansion [3][7]. - The integration of the Zoetis MFA portfolio is progressing well, with expectations for MFA growth to be flat to low-mid single digits long-term, targeting outperformance post-fiscal 2027 [4][6]. Market Dynamics - Strong end-market demand for animal-based protein and effective execution across segments contributed to recent performance [9]. - Consumer demand for meat, eggs, and dairy remains robust despite inflation, with demographic trends favoring high-quality protein consumption [10]. Competitive Positioning - Phibro is positioned as a strong competitor in the MFA market, likely ranking second globally, with key competitors including Elanco and Huvepharma [14]. - The company is also focusing on pricing adjustments during the integration of the Zoetis MFA portfolio to enhance margins [15]. Companion Animal Business - The company has launched a new product, Restoris, in the companion animal segment, which is expected to grow significantly over time [16]. - Management plans to reinvest profits from this segment while maintaining fiscal conservatism [16]. Leadership Transition - Dani Bendheim is set to become CEO later this year, with a focus on continuity in strategy and operations [3][17]. - The broader management team will remain in place, ensuring stability during the transition [18].

Summary of Phibro Animal Health Conference Call Company Overview - **Company**: Phibro Animal Health (NasdaqGM: PAHC) - **Date**: February 26, 2026 - **Key Speakers**: Dani Bendheim (Chief Strategy Officer and incoming CEO), Glenn David (CFO), Larry Miller (COO) Key Points Financial Performance - **Fiscal 2Q Results**: - Revenue growth of **21%** year-over-year - Adjusted net income growth of **60%** - Total revenue for the quarter was **$94 million** [5][6] - **Legacy MFA Business**: - Experienced a **5% decline** due to timing of orders from a major customer, but normalized growth was around **3%** [5][6] - **Vaccine Portfolio**: - Grew by **13%** - **Nutritional Specialty**: - Grew by **9%** - **Guidance Update**: - Confidence to raise guidance for revenue, EBITDA, and adjusted net income for the year [6][7] Strategic Developments - **Zoetis Acquisition**: - Integration of the Zoetis Medicated Feed Additive (MFA) portfolio is progressing well, expected to enhance overall business [11][12] - Anticipated growth in MFA portfolio to be flat to low mid-single digits in the long term, with vaccines and nutritional specialties expected to grow mid to high single digits [12][13] - **Market Dynamics**: - Strong demand for animal-based protein consumption is driving growth in the livestock market [20][24] - The company is focusing on building relationships with customers and addressing new disease challenges [21][22] Competitive Landscape - **Positioning**: - Phibro is positioned as a strong competitor in the MFA market, likely the **number two globally** [47][48] - Competes with Elanco and Huvepharma in the MFA space, while facing more competition in vaccines from Zoetis, Merck, and others [48][49] - **Market Share**: - Growth in sales suggests potential market share expansion, particularly through innovation and addressing emerging diseases [52] Pricing Strategy - **Pricing Power**: - The company has identified opportunities for price adjustments, particularly in acquired products, without significant volume drops [54][56] - Future price increases are expected to be low single-digit as products mature [58] Companion Animal Business - **Growth Potential**: - Companion animal products like Restoris and Regensa are showing strong growth, with plans to reinvest profits into this segment [61][62] - **Long-term Strategy**: - Aiming to establish the companion animal segment as a fourth pillar alongside MFAs, nutritional specialties, and vaccines [63] Margin Expansion - **Drivers of Margin Growth**: - Positive mix dynamics, growth in higher-margin products, and initiatives from the Phibro Forward program are contributing to margin expansion [65][66] - **Future Outlook**: - The company expects to continue driving income growth faster than revenue, with Phibro Forward hitting its peak in fiscal year 2027 [67] Leadership Transition - **CEO Transition**: - Dani Bendheim will take over as CEO, emphasizing continuity in strategy and operations [70][72] Additional Insights - **Cultural Integration**: - The integration of Zoetis employees and culture has been positive, with excitement about the new direction [40][41] - **Customer Reception**: - Positive feedback from customers regarding the expanded product portfolio and support [44][45] This summary encapsulates the key points discussed during the Phibro Animal Health conference call, highlighting financial performance, strategic developments, competitive positioning, pricing strategies, and future outlook.

Summary of Fibro Animal Health Conference Call Company Overview - **Company Name**: Fibro Animal Health - **Ticker Symbol**: PAHC - **Founded**: 1946 - **Employees**: Approximately 2,300 - **Manufacturing Plants**: 6 to 18 worldwide - **Product Registrations**: About 22,000 - **Global Reach**: Customers in approximately 100 countries - **Fiscal Year End**: June 30 Industry Context - **Sector**: Food Animal Health - **Market Demand**: The global population is expected to reach 10 billion in the next couple of decades, necessitating a 70% increase in animal-based protein production [4][4] - **Sustainability Focus**: The company aims to produce more with fewer natural resources, emphasizing animal health and welfare [4][4] Financial Performance - **Fiscal Year 2024 Revenue**: Achieved $1 billion before the acquisition of Zoetis' medicated feed additive business [6][6] - **Pro Forma Revenue Post-Acquisition**: Expected to reach approximately $1.4 billion [15][15] - **EBITDA Margins**: Targeted low 20% margins; currently achieving mid to high 20% margins on the acquired business [15][15] - **Sales Growth**: Legacy business sales up 8% year-over-year; EBITDA up 26% [21][21] - **Guidance for Fiscal Year**: Net sales projected between $1.26 billion and $1.29 billion, with EBITDA between $177 million and $183 million [29][29] Acquisition Insights - **Acquisition of Zoetis MFA Business**: - Completed integration process deemed successful [14][14] - Acquisition was strategic, enhancing revenue diversification and market presence [11][11] - Introduced new geographies and balanced product offerings across species [16][16] - Sales from Zoetis products in the first five months totaled $113 million, with a full-year estimate of $350 million [30][30] Product Portfolio - **Core Product Categories**: - **Medicated Feed Additives**: Includes antimicrobials, antioxidants, and anthelmintics [22][22] - **Nutritional Specialties**: Non-medicated products aimed at maintaining animal health [25][25] - **Vaccines**: Primarily poultry vaccines, including custom autogenous vaccines [27][28] Market Trends and Opportunities - **Geographic Expansion**: Increased focus on Europe, which previously represented only 8% of the Zoetis business [18][18] - **Species Focus**: Strengthened presence in beef and swine markets, particularly in the U.S. [42][42] - **Sustainability Market**: Recognized as a growing opportunity, particularly in dairy, with potential for technology solutions to address environmental concerns [59][60] Challenges and Future Outlook - **Headwinds**: Anticipated tariffs could impact EBITDA by $5 million to $10 million [34][34] - **Transformation Initiative**: "Fiber Forward" aims to enhance income growth through cost and sales strategies [34][34] - **Long-term Growth**: Positive outlook for continued growth across all business lines, with a focus on vaccines, nutritional specialties, and medicated feed additives [32][32] Conclusion Fibro Animal Health is positioned for significant growth following its acquisition of Zoetis' MFA business, with a strong focus on sustainability and expanding its market presence across various species and geographies. The company is optimistic about its financial performance and future opportunities in the animal health sector.